Table 2.
Summary of the significant parameters for different malignant grades and molecular subtypes
| Emax (kPa) | fmass (Hz) | Dmax (mm) | NV | mvFD | NB | |
|---|---|---|---|---|---|---|
| Histologic type | ||||||
| Benign (310) | ||||||
| Fibroadenoma (109) | 49.5 ± 33.8 | 143.0 ± 64.5 | 448.6 ± 262.8 | 5.9 ± 9.8 | 0.92 ± 0.43 | 2.8 ± 6.2 |
| Benign changes (77) | 44.5 ± 38.6 | 146.4 ± 94.0 | 356.9 ± 291.6 | 2.9 ± 5.4 | 0.83 ± 0.38 | 1.2 ± 2.6 |
| Fibrocystic changes (30) | 48.6 ± 31.9 | 171.1 ± 104.4 | 429.3 ± 282.6 | 4.4 ± 7.9 | 0.87 ± 0.43 | 1.7 ± 4.0 |
| Papilloma (28) | 51.8 ± 39.2 | 186.7 ± 88.3 | 454.0 ± 273.3 | 3.4 ± 4.2 | 0.95 ± 0.28 | 1.3 ± 1.8 |
| PASH (22) | 36.3 ± 28.3 | 139.8 ± 79.6 | 438.7 ± 247.5 | 3.1 ± 3.8 | 0.95 ± 0.27 | 1.0 ± 1.6 |
| Fat necrosis (18) | 97.1 ± 70.6 | 203.5 ± 184.1 | 574.9 ± 106.2 | 3.9 ± 3.0 | 1.1 ± 0.11 | 1.5 ± 1.3 |
| Atypical (14) | 51.2 ± 34.3 | 192.3 ± 105.3 | 303.4 ± 305.7 | 5.1 ± 9.9 | 0.75 ± 0.48 | 2.7 ± 5.6 |
| Duct ectasia (6) | 45.9 ± 20.7 | 231.8 ± 86.7 | 501.0 ± 270.8 | 2.5 ± 2.1 | 0.95 ± 0.19 | 0.5 ± 0.5 |
| Adenoma (4) | 47.9 ± 29.1 | 99.2 ± 56.2 | 655.4 ± 165.2 | 22 ± 22.7 | 1.28 ± 0.23 | 10.5 ± 13.0 |
| Others (2) | 103.0 ± 95.8 | 243.9 ± 71.1 | 708.5 ± 238.7 | 10 ± 11.3 | 1.24 ± 0.25 | 7 ± 8.5 |
| p valuea | .03 | .02 | .03 | .003 | .01 | .06 |
| Malignant (204) | ||||||
| IDC (136) | 161.6 ± 65.1 | 212.3 ± 124.9 | 640.9 ± 197.3 | 15.2 ± 15.9 | 1.19 ± 0.21 | 7.4 ± 9.2 |
| IMC with mixed ductal and lobular features (27) | 174.7 ± 68.3 | 227.8 ± 139.1 | 593.0 ± 278.2 | 17.0 ± 18.4 | 1.16 ± 0.23 | 8.2 ± 10.1 |
| ILC (24) | 168.8 ± 56.2 | 241.1 ± 128.9 | 567.6 ± 268.8 | 14.6 ± 25.0 | 1.14 ± 0.19 | 7.3 ± 14.6 |
| DCIS (15) | 94.6 ± 74.5 | 253.3 ± 172.6 | 503.8 ± 291.7 | 7.3 ± 5.9 | 1.11 ± 0.23 | 3.7 ± 3.4 |
| Other (2) | 154.1 ± 48.5 | 97.2 ± 90.6 | 811.4 ± 142.3 | 100 ± 76.4 | 1.50 ± 0.13 | 69 ± 46.7 |
| p valuea | .55 | .48 | .22 | .33 | .21 | .31 |
| Histologic grade | ||||||
| I (54) | 139.1 ± 69.2 | 278.5 ± 117.1 | 553.6 ± 244.3 | 7.5 ± 8.3 | 1.10 ± 0.20 | 3.5 ± 4.4 |
| II (92) | 168.0 ± 66.0 | 220.6 ± 140.7 | 617.7 ± 210.2 | 15.0 ± 16.3 | 1.18 ± 0.18 | 7.3 ± 9.2 |
| III (54) | 165.8 ± 64.2 | 155.6 ± 90.8 | 673.9 ± 233.5 | 24.1 ± 28.6 | 1.24 ± 0.24 | 12.4 ± 18.3 |
| p valuea | .05 | < .001 | .02 | < .001 | < .001 | < .001 |
| Molecular subtypes | ||||||
| Luminal A (76) | 155.7 ± 66.4 | 257.3 ± 120.5 | 577.0 ± 241.4 | 10.8 ± 14.2 | 1.13 ± 0.21 | 5.2 ± 8.0 |
| Luminal B (HER2-) (58) | 176.4 ± 61.4 | 218.2 ± 139.0 | 625.5 ± 181.0 | 15.2 ± 15.7 | 1.18 ± 0.16 | 7.4 ± 9.3 |
| Luminal B (HER2 +) (21) | 198.4 ± 49.8 | 136.2 ± 98.4 | 727.1 ± 155.5 | 28.6 ± 32.6 | 1.30 ± 0.13 | 14.5 ± 21.8 |
| HER2 + (4) | 169.1 ± 31.5 | 95.5 ± 33.2 | 628.7 ± 149.6 | 15.8 ± 14.5 | 1.20 ± 0.18 | 7.3 ± 6.4 |
| TNBC (20) | 131.6 ± 65.4 | 189.3 ± 85.6 | 543.2 ± 311.5 | 13.9 ± 16.3 | 1.11 ± 0.35 | 7.3 ± 10.8 |
| p valuea | .005 | < .001 | .07 | .002 | .01 | .02 |
Numbers are mean ± standard deviation, numbers in parentheses are numbers of participants
DCIS, ductal carcinoma in situ. IDC, invasive ductal carcinoma. ILC, invasive lobular carcinoma. IMC with mixed ductal and lobular features, invasive mammary carcinoma with mixed ductal and lobular features. PASH, pseudoangiomatous stromal hyperplasia. TNBC, triple negative breast cancer
aKruskal-Wallis test